Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-Human Dose Study of IOA-244 in Patients With Advanced or Metastatic Cancers

Next Previous
Trial Profile

First-in-Human Dose Study of IOA-244 in Patients With Advanced or Metastatic Cancers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roginolisib (Primary) ; Avelumab; Cisplatin; Pemetrexed; Ruxolitinib
  • Indications Anaplastic large cell lymphoma; Follicular lymphoma; Malignant melanoma; Malignant-mesothelioma; Mesothelioma; Myelofibrosis; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Peripheral T-cell lymphoma; Skin cancer; Solid tumours; T-cell lymphoma; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Acronyms DIONE-01
  • Sponsors iOnctura

Most Recent Events

  • 30 Apr 2025 Results assessing data from a comprehensive translational analyses of genomic, transcriptomic, proteomic and cellular data from uveal melanoma ,presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 11 Dec 2024 According to an iOnctura media release, results from this study to be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) annual congress tomorrow, 12 December at 12:30 CET (presentation 164P).
  • 11 Dec 2024 Results presented in the iOnctura Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top